NKGen Biotech will present a poster at the CTAD 2026 conference detailing long-term cognitive outcomes of troculeucel, an NK cell therapy, in a patient with moderate Alzheimer’s disease. The data comes from a Phase 1 study and an open-label extension where the patient received an additional 12 months of treatment. This presentation highlights potential benefits of troculeucel for neurodegenerative diseases and marks progress in its clinical development. NKGen continues to advance this novel immunotherapy toward market approval.
NKGen Biotech's upcoming presentation on troculeucel in moderate Alzheimer’s disease is noted here with Pluang's Health-sector market data as of Nov 09, 2026 19:41 WIB. Of 150 priced Health-sector US stocks tradable on Pluang, 121 rose and 18 fell today. Notable movers include IBRX at USD 7.49 with a -13.26% change, ABEO at USD 3.65 down -12.47%, and IMVT at USD 33.50 up +9.73%, with IMVT showing the highest gain.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
